In addition, the Russian Patent Office issued a first notification to grant patent coverage of the Company’s lead therapeutic candidate, NNI-351, for pharmaceutical composition and a method of treatment of Down syndrome mediated by Dyrk1a activity.
"We are pleased with the expansion of patent protection for our small-molecule therapies that each might improve the lives of people affected by neurological disorders, for which there are few, if any, therapeutic options," said Judith Kelleher-Andersson, Ph.D., Founder, President and Chief Executive Officer of Neuronascent.
Neuronascent’s new chemical entity is capable of entering the brain and increasing the number of new neurons that survive to maturity, which is associated with a reversal in cognitive deficits in animal models of Alzheimer’s disease.
NNI-362 is in FDA-required safety testing prior to testing in Alzheimer’s patients for its ability to reverse cognitive deficits by replacing neurons lost in the hippocampus of the brain.
Neuronascent’s lead candidate for neuropsychiatric disorders increases the proliferation of neuronal progenitors resulting in an increased number of new neurons in animal models of disease, including Down syndrome.
These new neurons are associated with improvements in behavior, specifically attention, memory and hyperactivity. These are often behavioral deficits observed in individuals with Down syndrome.